Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
$40.29
$0.18(0.88%)
At close: 4:00 PM EST
$40.29
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$17.82 - $42.05
Previous CloseN/A
Volume84.12K
Average Volume (3M)483.92K
Market Cap
$3.08B
Enterprise Value$2.77B
Total Cash (Recent Filing)$352.10M
Total Debt (Recent Filing)$9.72M
Price to Earnings (P/E)89.9
Beta0.63
Next Earnings
Mar 03, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding45,161,020
10 Day Avg. Volume397,232
30 Day Avg. Volume483,918
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.22
Price to Sales (P/S)3.34
P/FCF Ratio55.59
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit6.23
Enterprise Value/Ebitda63.75
Forecast
1Y Price Target
$50.80Price Target Upside26.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.04
Revenue Forecast (FY)$668.82M
Bulls Say, Bears Say
Bulls Say
Cash Flow And ExpansionKiniksa is at a pivotal stage of the company's lifecycle as it is cash flow positive, has plenty of room to expand Arcalyst's reach, and has a derisked, next-gen asset (KPL-387) to extend the franchise.
Market Penetration And ExpansionThere is significant room to continue to expand Arcalyst's opportunity, as the number of prescribers that have written Arcalyst still represents only a fraction of the potential prescribers.
Sales GrowthArcalyst generated $1B+ of sales driven by 16 consecutive quarters of growth with no signs of slowing.
Bears Say
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $17.82 and its highest was $42.05 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $3.08B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 109 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Oct 28, 2025. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.324 by -$0.094.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.41.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 45,161,020 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.23 in its last earnings report, missing expectations of $0.324. Following the earnings report the stock price went down -2.882%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.80 (26.09% Upside)
$50.80 (26.09% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 671.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 30.5%
Last 30 Days ▲ 30.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.51%
12-Months-Change
Fundamentals
Return on Equity
7.39%
Trailing 12-Months
Asset Growth
28.28%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with serious and unmet medical needs. The company operates primarily in the immunology and rare disease sectors, with a portfolio of product candidates targeting various conditions. Kiniksa's lead product is etokimab, an investigational monoclonal antibody designed to treat inflammatory diseases, which reflects the company's commitment to addressing complex health issues through advanced biopharmaceutical solutions.
KNSA Company Deck
KNSA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Kiniksa Pharmaceuticals with significant revenue growth, increased sales guidance, and a robust financial position. The company highlights the increased adoption of ARCALYST and its FDA Orphan Drug Designation for KPL-387. However, challenges remain with limited market penetration and increased operating expenses.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$50.80
▲(26.09% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
7.63% Insiders
15.51% Mutual Funds
0.32% Other Institutional Investors
65.79% Public Companies and Individual Investors